(Q38357590)

2 September 2017

1 reference

title

Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

2 September 2017

0 references

0 references

1

1 reference

2 September 2017

Till Sprenger

3

0 references

Ludwig Kappos

series ordinal

2

object named as

Ludwig Kappos

1 reference

PubMed ID

25687236

2 September 2017

language of work or name

English

0 references

publication date

17 February 2015

1 reference

Expert Opinion on Drug Safety

2 September 2017

1 reference

2 September 2017

14

1 reference

2 September 2017

5

1 reference

2 September 2017

749-759

1 reference

Teriflunomide and its mechanism of action in multiple sclerosis

2 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Leflunomide: mode of action in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Dietary nucleotides and gut mucosal defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Evidence supporting a role for dihydroorotate dehydrogenase, bioenergetics, and p53 in selective teriflunomide-induced apoptosis in transformed versus normal human keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Teriflunomide: a novel oral treatment for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Safety evaluation of leflunomide in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Peripheral neuropathy in patients treated with leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Leflunomide-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Birth outcomes in women who have taken leflunomide during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Pregnancy outcome in women exposed to leflunomide before or during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

The pill times 2: what every woman with multiple sclerosis should know

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

A successful pregnancy in a patient with Takayasu's arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Maternal exposure to leflunomide and methotrexate in a patient with adult-onset Still's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

Risk factors in miscarriage: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1014795

10.1517/14740338.2015.1014795

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

25687236